{"id":517321,"date":"2021-07-26T07:08:13","date_gmt":"2021-07-26T11:08:13","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/uniqure-announces-second-quarter-2021-financial-results-and-highlights-recent-company-progress\/"},"modified":"2021-07-26T07:08:13","modified_gmt":"2021-07-26T11:08:13","slug":"uniqure-announces-second-quarter-2021-financial-results-and-highlights-recent-company-progress","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/uniqure-announces-second-quarter-2021-financial-results-and-highlights-recent-company-progress\/","title":{"rendered":"uniQure Announces Second Quarter 2021 Financial Results and Highlights Recent Company Progress"},"content":{"rendered":"
\n

\n ~ Expanded gene therapy pipeline with four new research programs and announced acquisition
<\/em>
\n of Corlieve Therapeutics <\/em>
\n ~<\/em>\n <\/p>\n

\n ~ Presented positive 52-week data from HOPE-B pivotal study demonstrating sustained increases in<\/em>
\n
\n Factor IX (FIX) levels with mean FIX activity of 41.5 percent of normal and significant reductions in bleeding events ~<\/em>\n <\/p>\n

\n ~ Completed its<\/em>
\n global commercialization and license transaction with CSL Behring<\/em>
\n
\n for hemophilia B gene therapy program <\/em>
\n ~<\/em>\n <\/p>\n

\n ~ Initiated patient enrollment in second dose cohort of Phase I\/II clinical trial of AMT-130 for Huntington\u2019s
disease, with initiation of a European Phase Ib\/II clinical trial expected in second half of 2021 ~<\/em>\n <\/p>\n

LEXINGTON, Mass. and AMSTERDAM, The Netherlands, July 26, 2021 (GLOBE NEWSWIRE) — uniQure<\/a> N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today reported its financial results for the second quarter of 2021 and highlighted recent progress across its business.<\/p>\n

\u201cWe had a highly productive second quarter of this year marked by several notable achievements, including the closing on our global commercial licensing agreement with CSL Behring in hemophilia B and the recent presentation of 52-week data on all patients in our HOPE-B pivotal study showing durable and sustained increases in Factor IX levels within the non-hemophiliac range1<\/sup>, as well as significant reductions in both bleeding events and usage of replacement therapy after a one-time administration of etranacogene dezaparvovec,\u201d stated Matt Kapusta, chief executive officer at uniQure.<\/a> \u201cAdditionally, we continued to make strong progress in our U.S. Phase I\/II study of AMT-130 in Huntington\u2019s disease, including the completion of patient enrollment in the first dose cohort and the initiation of dosing in the second cohort.\u201d<\/p>\n

\u201cWe also recently hosted a Research and Development Day where we disclosed four new promising research programs that complemented our expanding focus in neurological disease and larger patient populations, including the acquisition of Corlieve Therapeutics and its gene therapy program targeting temporal lobe epilepsy that builds on our expanding focus in serious neurological diseases,\u201d he added. \u201cThese investments deliver on our commitment to leverage our strong cash position to invest in new research programs and enabling technologies with the potential to drive significant value. In the second half of 2021, we expect to continue our progress across all programs, including availability of 78-week data from the HOPE-B study, initiating patient enrollment for our open-label European study of AMT-130 in Huntington\u2019s disease, and announcing initial data on the first four randomized Huntington\u2019s disease patients in the ongoing U.S. Phase I\/II study.\u201d<\/p>\n

\n 1<\/sup> Srivastava et al, Haemophilia. 2020;26(Suppl 6):1\u2013158.<\/p>\n

\n Recent Company Progress <\/strong>\n <\/p>\n